
浏览全部资源
扫码关注微信
1.湖南中医药大学,长沙 410208
2.中医方证研究转化医学湖南省重点实验室,长沙 410208
3.贵州中医药大学,贵阳 550025
谭艳,在读博士,从事仲景杂病及经方应用基础研究,E-mail:1402245779@qq.com
* 喻嵘,教授,博士生导师,从事仲景杂病及经方应用基础研究,Tel:0731-88458072,E-mail:yuron@21.cn.com
收稿日期:2021-04-21,
网络出版日期:2021-09-22,
纸质出版日期:2021-11-05
移动端阅览
谭艳,周聪,黄柔等.茵陈蒿汤对MKR鼠2型糖尿病合并非酒精性脂肪性肝病的作用[J].中国实验方剂学杂志,2021,27(21):105-113.
TAN Yan,ZHOU Cong,HUANG Rou,et al.Effect of Yinchenhao Tang on Type 2 Diabetes Mellitus Complicated with Non-alcoholic Fatty Liver Disease in MKR Mice[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(21):105-113.
谭艳,周聪,黄柔等.茵陈蒿汤对MKR鼠2型糖尿病合并非酒精性脂肪性肝病的作用[J].中国实验方剂学杂志,2021,27(21):105-113. DOI: 10.13422/j.cnki.syfjx.20212195.
TAN Yan,ZHOU Cong,HUANG Rou,et al.Effect of Yinchenhao Tang on Type 2 Diabetes Mellitus Complicated with Non-alcoholic Fatty Liver Disease in MKR Mice[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(21):105-113. DOI: 10.13422/j.cnki.syfjx.20212195.
目的
2
探讨茵陈蒿汤对MKR鼠2型糖尿病合并非酒精性脂肪性肝病的作用机制。
方法
2
8周龄MKR小鼠40只高脂喂养8周后,随机分为模型组、茵陈蒿汤原方剂量组(17.16 g·kg
-1
),茵陈蒿汤教材剂量组(4.68 g·kg
-1
),二甲双胍+辛伐他汀组[(65+2.6)×10
-3
g·kg
-1
)],同龄MKR鼠10只作为空白组,FVB鼠10只分别作为正常组。各组灌胃给药8周后,测定小鼠肝脏湿重,口服糖耐量(OGTT),血清炎性因子白细胞介素-6(IL-6),肿瘤坏死因子-
α
(TNF-α),血脂和肝功能的变化,透射电镜和苏木素-伊红(HE)染色对肝脏组织形态进行观察,蛋白免疫印迹法(Western blot)检测肝脏组织Toll样受体4(TLR4),髓样分化因子88(MyD88),核转录因子-
κ
B(NF-
κ
B)蛋白表达变化。
结果
2
与模型组比较,给药组小鼠肝湿重指数显著降低(
P
<
0.01),OGTT较模型组明显有所改善(
P
<
0.05),血清中IL-6,TNF-
α
含量显著降低(
P
<
0.01),形态学改变上,茵陈蒿汤对肝细胞结构有保护作用,减少肝细胞脂肪样变性;茵陈蒿汤可以明显下调T2DM合并NAFLD模型小鼠肝脏组织TLR4,MyD88,NF-
κ
B蛋白含量(
P
<
0.05),且对于TLR4,NF-
κ
B的下调,茵陈蒿汤原方剂量明显优于茵陈蒿汤剂量(
P
<
0.05)。
结论
2
茵陈蒿汤能降低炎症因子水平,肝组织TLR4,MyD88,NF-
κ
B的表达水平,改善肝脏病理损伤,干预MKR鼠T2DM合并NAFLD疾病状态,具有一定保护肝功能,降低血脂以及延缓肝脏炎症反应的作用。
Objective
2
To investigate the action mechanism of Yinchenhao Tang against type 2 diabetes mellitus (T2DM) complicated with non-alcoholic fatty liver disease (NAFLD) in MKR mice.
Method
2
Forty eight-week-old MKR mice were fed a high-fat diet for eight weeks and then divided into the model group,original Yinchenhao Tang (17.16 g·kg
-1
) group,Yinchenhao Tang group at a specified dose (4.68 g·kg
-1
) in teaching materials,and positive drug [metformin + simvastatin, (65+2.6)×10
-3
g·kg
-1
] group. Another 10 MKR mice of the same age were classified into the blank group and 10 FVB mice into the normal group. After eight weeks of intragastric administration in each group,the liver wet weight,oral glucose tolerance test (OGTT),serum inflammatory factors interleukin-6 (IL-6) and tumor necrosis factor-
α
(TNF-
α
),and changes in blood lipid and liver function were determined. Hematoxylin-eosin (HE) staining was conducted for observing the morphological changes in liver tissue under a transmission electron microscope,followed by the detection of Toll-like receptor 4 (TLR4),myeloid differentiation factor 88 (MyD88),and nuclear transcription factor-
κ
B (NF-
κ
B) protein expression by Western blot.
Result
2
Compared with the model group,the medication groups exhibited significantly reduced liver wet weight index (
P
<
0.01),improved OGTT result (
P
<
0.05),and down-regulated serum IL-6 and TNF-
α
levels (
P
<
0.01). In terms of morphological changes,Yinchenhao Tang protected the hepatocyte structure and alleviated hepatocyte steatosis. Moreover, Yinchenhao Tang obviously down-regulated the protein expression levels of TLR4,MyD88,and NF-
κ
B in liver tissue of MKR mice with T2DM combined with NAFLD (
P
<
0.05),and the down-regulation of TLR4 and NF-
κ
B in the original Yinchenhao Tang group was better than that in the Yinchenhao Tang group at a specified dose in teaching materials (
P
<
0.05).
Conclusion
2
Yinchenhao Tang is able to reduce inflammatory factor levels and down-regulate TLR4,MyD88,and NF-
κ
B expression in liver tissue to relieve the pathological liver injury and interfere with T2DM combined with NAFLD of MKR mice. It exerts a certain liver-protective effect by lowering the blood lipids and delaying the hepatic inflammation.
BRIL F , CUSI K . Management of nonalcoholic fatty liver disease in patients with type 2 diabetes:a call to action [J]. Diabetes Care , 2017 , 40 ( 3 ): 419 - 430 .
陈聪 , 陈家旭 , 喻嵘 , 等 . 左归降糖清脂方对2型糖尿病合并非酒精性脂肪性肝病MKR鼠肝组织PI3K信号通路的影响 [J]. 中华中医药杂志 , 2021 , 36 ( 1 ): 106 - 111 .
吴勇军 , 成细华 , 喻嵘 , 等 . 左归降糖清脂方对2型糖尿病转基因MKR鼠脂肪肝发生的影响 [J]. 中国实验方剂学杂志 , 2011 , 17 ( 5 ): 140 - 143 .
XU L , XIE T , SHEN T , et al . Yinchenhaotang for chronic hepatitis B:protocol for a systematic review and Meta-analysis [J]. Medicine , 2019 , 98 ( 8 ): e14648 .
李婉华 , 张桂贤 , 聂卫 , 等 . 加味茵陈蒿汤对大鼠胆汁淤积性肝病的治疗作用 [J]. 中国实验方剂学杂志 , 2020 , 26 ( 4 ): 29 - 34 .
付亚坤 , 闫丽辉 , 李新 , 等 . 茵陈蒿汤防治大鼠非酒精性脂肪性肝病效果及其对肝组织NTCP表达的影响 [J]. 山东医药 , 2019 , 59 ( 2 ): 40 - 43 .
程莉娟 , 成细华 , 喻嵘 , 等 . 内质网应激相关基因在2型糖尿病合并脂肪肝小鼠肝脏中的表达变化 [J]. 中国老年学杂志 , 2015 , 35 ( 2 ): 415 - 418 .
成细华 , 喻嵘 , 明霞 , 等 . 2型糖尿病合并非酒精性脂肪肝动物模型的建立 [J]. 胃肠病学和肝病学杂志 , 2011 , 20 ( 1 ): 77 - 80 .
魏冠德 . 左归降糖清脂方调控PPAR- α 、CYP2E1表达改善MKR转基因鼠2型糖尿病合并脂肪肝的作用研究 [D]. 长沙 : 湖南中医药大学 , 2012 .
XUE M , DERVISH S , HARRISON L C , et al . Activated protein C inhibits pancreatic islet inflammation,stimulates T regulatory cells,and prevents diabetes in non-obese diabetic(NOD) mice [J]. J Biol Chem , 2012 , 287 ( 20 ): 16356 - 16364 .
HAZLEHURST J M , WOODS C , MARJOT T , et al . Non-alcoholic fatty liver disease and diabetes [J]. Metabolism , 2016 , 65 ( 8 ): 1096 - 1108 .
SCHUSTER S , CABRERA D , ARRESE M , et al . Triggering and resolution of inflammation in NASH [J]. Nat Rev Gastroenterol Hepatol , 2018 , 15 ( 6 ): 349 - 364 .
YAN F J , WANG X , WANG S E , et al . C-Jun/C7ORF41/NF- κ B axis mediates hepatic inflammation and lipid accumulation in NAFLD [J]. Biochem J , 2020 , 477 ( 3 ): 691 - 708 .
庞敏 , 单宇 , 王菲菲 , 等 . 诸葛菜种子水提物对硫代乙酰胺诱导小鼠急性肝损伤的保护作用研究 [J]. 中国中药杂志 , 2020 , 45 ( 6 ): 1399 - 1405 .
SEKI E , BRENNER D A . Toll-like receptors and adaptor molecules in liver disease:update [J]. Hepatology , 2008 , 48 ( 1 ): 322 - 335 .
喻嵘 , 成细华 , 胡伟 , 等 . 骨骼肌特异性胰岛素样生长因子1及胰岛素双受体功能缺失鼠糖尿病发病及其相关炎症因子的变化 [J]. 中国组织工程研究与临床康复 , 2007 , 11 ( 45 ): 9075 - 9078 .
胡伟 , 喻嵘 , 成细华 , 等 . MKR转基因糖尿病小鼠血糖血脂与血清炎症因子CRP、IL-6、TNF- α 的相关性分析 [J]. 基础医学与临床 , 2009 , 29 ( 9 ): 987 - 988 .
程莉娟 , 成细华 , 喻嵘 , 等 . 滋阴益气活血解毒法治疗32例2型糖尿病合并非酒精性脂肪肝的临床观察 [J]. 中华中医药杂志 , 2013 , 28 ( 9 ): 2807 - 2810 .
周伟青 , 王修银 , 刘道利 , 等 . 茵陈蒿汤对NAFLD伴IR大鼠的肝保护作用及其机制 [J]. 山东医药 , 2019 , 59 ( 19 ): 18 - 22 .
0
浏览量
20
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621